ClinicalTrials.gg
RecruitingNCT07173933Updated Nov 17, 2026

Evaluation of the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)

A Phase 1/2 interventional study of GC310 in Wilson Disease, sponsored by GeneCradle Inc. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by GeneCradle Inc · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 17, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hepatolenticular Degeneration with a site in China — 10 open to participants now, 11 under way, 1 of them phase 3. Hepatolenticular Degeneration · China.

Started
2026
with 2 others
Phase 1/2
2 of 15
2 open now
Primary completion
2027-12
later than 5 of 10 live
Registered
12th of 15
by date
Lead sponsor
1 of 15
GeneCradle Inc

Among the 15 studies in Hepatolenticular Degeneration with a site in China, this one is one of 3 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 5 of the 10 other live ones, and was the 12th registered.

Hepatolenticular Degeneration

80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.

Browse Hepatolenticular Degeneration studies →

Open to participants now

10 of the 15 studies in Hepatolenticular Degeneration with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hepatolenticular Degeneration with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if GC310 (AAV5-ATP7B) gene therapy can treat Wilson's Disease (WD) in patients over the age of 18 years old. The main questions it aims to answer are:

Is GC310 safe and tolerable to WD patients? What is the recommended phase II dose (RP2D)? What is the change from baseline in 24-hour urinary copper concentration after 52 weeks of administration?

Participants will be administrated GC310 intravenously and be followed up for 52 weeks to observe drug safety, tolerability and efficacy .

03

Conditions studied

  • Wilson Disease

Keywords

  • gene therapy
  • Genecradle
  • AAV5
  • ATP7B
  • Wilson Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years, sex unrestricted;
  • Definitive diagnosis of Wilson disease (WD) based on:

    (i) or (ii) + (iii) and (iv), or (i) or (ii) + (v); (i) Neurological and/or psychiatric symptoms; (ii) Unexplained liver injury; (iii) Reduced serum ceruloplasmin and/or elevated 24-hour urinary copper; (iv) Positive corneal Kayser-Fleischer (K-F) ring; (v) Biallelic pathogenic ATP7B variants confirmed by segregation analysis and variant pathogenicity assessment;

  • Serum ceruloplasmin concentration \< ½ × lower limit of normal (LLN);
  • Willing and able to comply with all study procedures, and has provided written .

Exclusion criteria

Exclusion Criteria:

Subjects meeting ANY of the following criteria will be excluded:

  1. Screening serum anti-AAV5 neutralizing antibody titre > 1:100.
  2. laboratory abnormality at screening or baseline:

    1. or AST ≥ 5 × , direct > 1 × ULN, or albumin \< 1 × LLN;
    2. Blood ammonia > 1 × ULN.
  3. Renal impairment (any degree).
  4. Current hepatic decompensation or history of hepatic decompensation.
  5. Liver stiffness measurement (LSM) ≥ 15 kPa by transient elastography at screening.
  6. History of acute liver failure from any cause.
  7. Evidence of advanced liver disease defined by either:

    1. MELD score ≥ 12, or
    2. score ≥ 7.
  8. Severe neuro-psychiatric manifestations that, in the investigator's opinion, could compromise subject safety or interfere with study participation.
  9. Positive for antibody, antibody, Treponema pallidum antibody, or surface antigen.
  10. to therapy judged by the investigator (e.g., uncontrolled hypertension, systemic fungal infection, glaucoma, osteoporosis, active tuberculosis).
  11. Concurrent conditions that may interfere with study conduct or assessment, including significant gastrointestinal, cardiovascular, cerebrovascular, renal, endocrine, haematological, immunological, neurological or psychiatric disorders other than Wilson disease.
  12. Pregnant or lactating women.
  13. Women of or fertile men who plan to conceive within 1 year after dosing or are unwilling to use highly effective .
  14. Body-mass index ≥ 24 kg/m².
  15. History of severe to foods or drugs, including recombinant proteins.
  16. Vaccination within 2 weeks prior to planned dosing.
  17. Prior exposure to any gene-therapy product.
  18. Participation in any other clinical trial (WD-related or not) within 3 months before screening.
  19. Any other condition or circumstance that, in the opinion of the investigator, renders the subject unsuitable for the study (e.g., poor compliance).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    3.0E+13 d.vg/kg of GC310

    Single intravenous administration of GC310 at a dose of 3.0E+13 d.vg/kg

    Genetic: GC310

  • Experimental
    6.0E+13 d.vg/kg of GC310

    Single intravenous administration of GC301 at a dose of 6.0E+13 d.vg/kg

    Genetic: GC310

Interventions

  • GeneticGC310

    GC310 is an adeno-associated virus 5 (AAV5) vector delivering a functional copy of the truncated human ATP7B gene

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events after GC310 administration

    Time frame: within 12 weeks

  2. Incidence of dose-limiting toxicity (DLT) events after GC310 administration;

    Time frame: within 4 weeks

  3. Change from baseline in serum ceruloplasmin (CP) concentration after GC310 administration;

    Time frame: 52 weeks

  4. Change from baseline in 24-hour urinary copper excretion after GC310 administration.

    Time frame: 52 weeks

Secondary outcomes

  1. Change from baseline in the urinary copper-to-creatinine ratio

    Time frame: 52 weeks

  2. Change from baseline in ALT and AST levels

    Time frame: 52 weeks

  3. Change from baseline in hepatic imaging findings

    Time frame: 52 weeks

  4. Change from baseline in Kayser-Fleischer (K-F) rings observed by slit-lamp examination

    Time frame: 52 weeks

  5. Evaluation of adverse-event incidence

    Time frame: 52 weeks

  6. Serum anti-AAV5 and anti-ATP7B antibody levels

    Time frame: 52 weeks

  7. Change in blood GC310 vector genome copy number

    Time frame: 52 weeks

  8. AAV shedding

    Time frame: 52 weeks

Other outcomes

  1. Change from baseline in serum ceruloplasmin (CP) activity

    Time frame: 52 weeks

  2. Change from baseline in relative exchangeable copper (exchangeable copper/total serum copper)

    Time frame: 52 weeks

  3. Change from baseline in brain MRI findings

    Time frame: 52 weeks

  4. Change from baseline in liver biopsy findings

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start Oct 2025 → Feb 2026, primary completion Apr 2027 → Dec 2027 and completion Oct 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2025
First posted
Sep 15, 2025
StartActual
Feb 20, 2026was Oct 2025
Primary completionEst.
Dec 2027was Apr 2027
CompletionEst.
Dec 2028was Oct 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
Peking Union Medical College is now Recruiting
Nov 17, 2026
Start date
Oct 2025→Feb 20, 2026 (actual)
Nov 17, 2026
Primary completion
Apr 2027→Dec 2027
Nov 17, 2026
Study completion
Oct 2027→Dec 2028
Nov 17, 2026
Interventions
Arm changed Cohort 1→3.0E+13 d.vg/kg of GC310; Cohort 2→6.0E+13 d.vg/kg of GC310
Nov 17, 2026
Title
Phase I/II Clinical Study to EvaluateEvaluation of the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    Peking Union Medical College is now Recruiting
    Start date Oct 2025→Feb 20, 2026 (now actual)
    Primary completion Apr 2027→Dec 2027
    Study completion Oct 2027→Dec 2028
    Interventions Arm changed Cohort 1→3.0E+13 d.vg/kg of GC310; Cohort 2→6.0E+13 d.vg/kg of GC310
    Title Phase I/II Clinical Study to EvaluateEvaluation of the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07173933
Lead sponsor
GeneCradle Inc
Responsible party
Sponsor
First posted
Sep 15, 2025
Start date
Feb 20, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

GeneCradle, Inc China
Contact
ind@bj-genecradle.com
86-13501380583

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion